2-溴-6-(4-吗啉基)吡啶 | 332134-60-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-溴-6-(4-吗啉基)吡啶
• 中文别名: 4-(6-溴吡啶-2-基)吗啉；2-溴-6-吗啉吡啶；4-(6-溴-2-吡啶)吗啉
• 英文名称: 4-(6-bromopyridin-2-yl)morpholine
• 英文别名: 2-bromo-6-morpholinopyridine
• CAS: 332134-60-8
• 化学式: C₉H₁₁BrN₂O
• 分子量: 243.103
• InChiKey: RCGFRLCJCFDVOQ-UHFFFAOYSA-N

物化性质

• 熔点：
  50 °C
• 沸点：
  372.2±42.0 °C(Predicted)
• 密度：
  1.499±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(6-Bromopyridin-2-yl)morpholine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(6-Bromopyridin-2-yl)morpholine
CAS number: 332134-60-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H11BrN2O
Molecular weight: 243.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-6-(4-吗啉基)吡啶 在 Oxone 、 sodium hydroxide 、 potassium tert-butylate 、 sodium ethanolate 、 肼 作用下， 以 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 78.17h， 生成 2-(3,5-二甲基-吡唑-1-基)-6-(6-吗啉-4-基-吡啶-2-基)-嘧啶-4-基胺
  参考文献：
  名称：

  WO2008/116185

  摘要：

  公开号：
• 作为产物：
  描述：

  吗啉 、 2,6-二溴吡啶 在 potassium phosphate 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-溴-6-(4-吗啉基)吡啶
  参考文献：
  名称：

  芳基卤化物的无过渡金属胺化—一种简单而可靠的方法，可高效，高产地合成N-芳基化胺

  摘要：

  提出了一种简单，可靠的反应方案，用于在无过渡金属的反应条件下，由芳基卤化物与各种（也是位阻的）胺反应衍生而来的各种N-芳基化胺的清洁，快速和高产率合成。二恶烷和KN（Si（CH 3）3）2被发现是该转化的理想溶剂和基础。观察到的转化率和产率极好，并且在大多数反应中进行的反应明显高于其催化形式的反应。此外，几乎可以选择性合成6-卤代吡啶-2-胺和不对称吡啶-2,6-二胺（分别来自2,6-二溴吡啶和2,6-二氯吡啶的连续反应）。在非常短的反应时间内即可获得定量收率（相对于2,6-二卤代吡啶）。不需要纯化6-卤代吡啶-2-胺中间体，从而可以在“一锅法”中合成吡啶-2,6-二胺。但是，催化剂在许多情况下不是有效地和选择性地使芳基卤化物与胺偶联，使无过渡金属形式的Buchwald-Hartwig反应对于合成N-芳基化胺（在芳基卤化物上具有取代基的底物）极具吸引力，这会促进区域选择性和/或不需要区域选择性胺化。

  DOI：

  10.1016/j.tet.2008.11.072

文献信息

• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：ONTARIO INST FOR CANCER RES (OICR)

  公开号：WO2017147700A1

  公开（公告）日：2017-09-08

  The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：包括这些化合物的化合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、疾病或症状的药物。
• Preparation of 3,4-Substituted-5-Aminopyrazoles and 4-Substituted-2-Aminothiazoles
  作者：Stepan Havel、Prashant Khirsariya、Naresh Akavaram、Kamil Paruch、Benoit Carbain

  DOI：10.1021/acs.joc.8b02655

  日期：2018.12.21

  3,4-Substituted-5-aminopyrazoles and 4-substituted-2-aminothiazoles are frequently used intermediates in medicinal chemistry and drug discovery projects. We report an expedient flexible synthesis of 3,4-substituted-5-aminopyrazoles (35 examples), based on palladium-mediated α-arylation of β-ketonitriles with aryl bromides. A library of 4-substituted-2-aminothiazoles (21 examples) was assembled by a

  3,4-取代的5-氨基吡唑和4-取代的2-氨基噻唑是药物化学和药物开发项目中经常使用的中间体。我们报道了基于钯介导的β-酮腈与芳基溴化物的α-芳基化反应的3,4-取代的5-氨基吡唑类化合物的便捷合成（35个例子）。通过使用新制备的，适当保护的4-硼酸-2-氨基噻唑的频哪醇酯和MIDA酯与（杂）芳基卤化物的Suzuki偶联的序列，组装4-取代的2-氨基噻唑的文库（21个实例）。
• Access to 2-Aminopyridines - Compounds of Great Biological and Chemical Significance
  作者：Jeanne L. Bolliger、Miriam Oberholzer、Christian M. Frech

  DOI：10.1002/adsc.201000942

  日期：2011.4.18

  products, medicinally important compounds, and organic materials and thus, extremely valuable synthetic targets. The few reported 6‐substituted 2‐aminopyridines and the lack of flexible, efficient and general applicable methods for their synthesis demonstrates the urgent need of new methods for their preparation. Reactions between 2,6‐dibromopyridine and primary or secondary, cyclic or acyclic, and aliphatic

  2-氨基吡啶是生物活性天然产物，重要医学化合物和有机材料的关键结构核心，因此，它们是非常有价值的合成靶标。少数报道的6-取代的2-氨基吡啶和缺乏灵活，有效和通用的合成方法表明了对制备其新方法的迫切需要。2,6-二溴吡啶和伯或仲的，环状或无环的，以及脂族或芳族胺之间的反应进行了示出，以选择性地得到相应的6-溴吡啶-2-胺在非常高的产率，其被成功地用作今后的C基板 Ç交叉偶联反应。最近推出的二氯双[1-（二环己基膦酰基）哌啶]钯（1）用作6-溴吡啶-2-胺与芳基硼酸，二芳基和二烷基锌试剂或烯烃的交叉偶联催化剂，因此，也是此类底物的出色的CC交叉偶联催化剂。而且，所提出的所有反应方案均在均匀应用的每种催化剂中使用。胺化反应和交叉偶联反应的范围都得到了很好的定义，可以使反应方案直接直接适用于其他胺和/或偶联伙伴，因此首次提供了非常灵活且普遍适用的反应方案获得2-氨基吡啶。
• [EN] TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS<br/>[FR] TETRAHYDRONAPHTHYLPIPER- AZINES UTILISEES EN TANT QU'AGONISTES INVERSES, AGONISTES PARTIELS ET ANTAGONISTES DE 5-HT1B
  申请人：PFIZER PROD INC

  公开号：WO2005113527A1

  公开（公告）日：2005-12-01

  The present invention relates to novel tetrahydronaphthylpiperazines derivatives, that are compounds of the formula (I) wherein R1, R2 and R6 are as defined herein, X is CH2 or O, A is a group of the formula (G1, G2, G2a, G3, G4, G5 or G6) depicted below, and D is a group of the formula (D), wherein Y, W and Z are C or N and wherein R7 is as defined herein and their salts and compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors. Compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated.

  本发明涉及新型四氢萘哌嗪衍生物，即式(I)中R1、R2和R6如本文所定义，X为CH2或O，A为下图所示的式(G1、G2、G2a、G3、G4、G5或G6)的基团，D为式(D)的基团，其中Y、W和Z为C或N，R7如本文所定义，以及它们的盐和组合物，包括选择性5-羟色胺1(5-HT1)受体的拮抗剂、逆向激动剂和部分激动剂。本发明的化合物在治疗或预防抑郁症、焦虑症、强迫症(OCD)和其他需要5-HT1激动剂或拮抗剂的疾病中具有用途。
• [EN] PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2<br/>[FR] PYRAZOLOPYRIDINES COMME INHIBITEURS DE LA KINASE LRRK2
  申请人：MEDICAL RES COUNCIL TECHNOLOGY

  公开号：WO2012038743A1

  公开（公告）日：2012-03-29

  The present invention relates to compounds of formula I, or pharmaceutically acceptable salts or esters thereof, (Formula I) wherein R1 is selected from: aryl; heteroaryl; -NHR3; fused aryl-C4_7-heterocycloalkyl; -CONR4R5; - NHCOR6; -C3-7-cycloalkyl,-NR3R6; -OR3; OH; NR4R5; and alkyl optionally substituted with a substituent selected from R11 and a group A; wherein said aryl, heteroaryl, fused aryl-C4-7-heterocycloalkyl and C4-7- heterocycloalkyi are each optionally substituted with one or more substituents selected from C1-6-alkyl, C3-7-cycloalkyl, heteroaryl, C4-7-heterocycloalkyl, aryl and a group A, and said C1-6-alkyl, C3-7-cycloalkyl, heteroaryl, C4-7-heterocycloalkyl, and aryl substituents are in turn each optionally substituted with one or more groups selected from R11 and a group A; R2 is selected from hydrogen, aryl, C1-6-alkyl, C2-6-alkenyl, C3-7-cycloalkyl, heteroaryl, heterocycloalkyi, fused aryl-C4-7-rheterocycloalkyl and halogen, wherein said C1-6-alkyl, C2-6-alkenyl, aryl, heteroaryl, fused aryl-C4-7-heterocycloalkyl and C4-7-heterocycloalkyl are each optionally substituted with one or more substituents selected from R11 and A. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds.

  本发明涉及式I的化合物，或其药学上可接受的盐或酯，其中R1选自：芳基；杂环芳基；-NHR3；融合芳基-C4_7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基，-NR3R6；-OR3；OH；NR4R5；和烷基，可选择地被来自R11和A组的取代基取代；其中所述的芳基，杂环芳基，融合芳基-C4-7-杂环烷基和C4-7-杂环烷基可分别被来自C1-6-烷基，C3-7-环烷基，杂环芳基，C4-7-杂环烷基，芳基和A组的一个或多个取代基取代，而所述的C1-6-烷基，C3-7-环烷基，杂环芳基，C4-7-杂环烷基和芳基取代基又可分别被来自R11和A组的一个或多个基团取代；R2选自氢，芳基，C1-6-烷基，C2-6-烯基，C3-7-环烷基，杂环芳基，杂环烷基，融合芳基-C4-7-杂环烷基和卤素，其中所述的C1-6-烷基，C2-6-烯基，芳基，杂环芳基，融合芳基-C4-7-杂环烷基和C4-7-杂环烷基可分别被来自R11和A的一个或多个取代基取代。进一步方面涉及所述化合物的药物组合物和治疗用途。